360 related articles for article (PubMed ID: 29463421)
21. Vaccination against herpes zoster in developed countries: state of the evidence.
Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
[TBL] [Abstract][Full Text] [Related]
22. Cost and utility in immunocompromised subjects who developed herpes zoster during the randomized V212 inactivated varicella-zoster vaccine (ZV
Eriksson J; Hunger M; Bourhis F; Thorén R; Popmihajlov Z; Finelli L; Jiang Y
Expert Rev Pharmacoecon Outcomes Res; 2020 Dec; 20(6):613-621. PubMed ID: 31721601
[No Abstract] [Full Text] [Related]
23. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
James SF; Chahine EB; Sucher AJ; Hanna C
Ann Pharmacother; 2018 Jul; 52(7):673-680. PubMed ID: 29457489
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and Safety of an Adjuvanted Herpes Zoster Subunit Vaccine Coadministered With Seasonal Influenza Vaccine in Adults Aged 50 Years or Older.
Schwarz TF; Aggarwal N; Moeckesch B; Schenkenberger I; Claeys C; Douha M; Godeaux O; Grupping K; Heineman TC; Fauqued ML; Oostvogels L; Van den Steen P; Lal H
J Infect Dis; 2017 Dec; 216(11):1352-1361. PubMed ID: 29029224
[TBL] [Abstract][Full Text] [Related]
25. Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status.
Marin M; Yawn BP; Hales CM; Wollan PC; Bialek SR; Zhang J; Kurland MJ; Harpaz R
Hum Vaccin Immunother; 2015; 11(5):1157-64. PubMed ID: 25806911
[TBL] [Abstract][Full Text] [Related]
26. Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older.
Curran D; Oostvogels L; Heineman T; Matthews S; McElhaney J; McNeil S; Diez-Domingo J; Lal H; Andrews C; Athan E; Berglund J; Campora L; de Looze F; Korhonen T; Leung E; Levin M; Volpi A; Johnson RW;
J Gerontol A Biol Sci Med Sci; 2019 Jul; 74(8):1231-1238. PubMed ID: 29955836
[TBL] [Abstract][Full Text] [Related]
27. Safety of the adjuvanted recombinant zoster vaccine in adults aged 50 years or older. A phase IIIB, non-randomized, multinational, open-label study in previous ZOE-50 and ZOE-70 placebo recipients.
Ocran-Appiah J; Boutry C; Hervé C; Soni J; Schuind A;
Vaccine; 2021 Jan; 39(1):6-10. PubMed ID: 33277059
[TBL] [Abstract][Full Text] [Related]
28. A retrospective cohort study evaluating the incidence of herpes zoster and postherpetic neuralgia after a live attenuated Oka-strain herpes zoster vaccine in a real-world setting in Japan.
Yaegashi M; Matsui H; Yoshida A; Ban H; Miyazaki R; Oda N; Hattori K; Motomura Y; Usami H; Matsushita H
Vaccine; 2024 Jan; 42(3):464-470. PubMed ID: 38172019
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.
Godeaux O; Kovac M; Shu D; Grupping K; Campora L; Douha M; Heineman TC; Lal H
Hum Vaccin Immunother; 2017 May; 13(5):1051-1058. PubMed ID: 28068212
[TBL] [Abstract][Full Text] [Related]
30. Potential cost-effectiveness of adjuvanted herpes zoster subunit vaccine for older adults in Hong Kong.
You JHS; Ming WK; Lee CF; Tsang OT; Chan PK
Vaccine; 2018 Jul; 36(31):4610-4620. PubMed ID: 29958739
[TBL] [Abstract][Full Text] [Related]
31. A novel vaccine (Zostavax) to prevent herpes zoster and postherpetic neuralgia.
Holcomb K; Weinberg JM
J Drugs Dermatol; 2006 Oct; 5(9):863-6. PubMed ID: 17039651
[TBL] [Abstract][Full Text] [Related]
32. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
Johnson RW
Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
[TBL] [Abstract][Full Text] [Related]
33. Adjuvanted recombinant zoster vaccine decreases herpes zoster-associated pain and the use of pain medication across 3 randomized, placebo-controlled trials.
Kim JH; Johnson R; Kovac M; Cunningham AL; Amakrane M; Sullivan KM; Dagnew AF; Curran D; Schuind A
Pain; 2023 Apr; 164(4):741-748. PubMed ID: 36066965
[TBL] [Abstract][Full Text] [Related]
34. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
35. Long-term persistence of zoster vaccine efficacy.
Morrison VA; Johnson GR; Schmader KE; Levin MJ; Zhang JH; Looney DJ; Betts R; Gelb L; Guatelli JC; Harbecke R; Pachucki C; Keay S; Menzies B; Griffin MR; Kauffman CA; Marques A; Toney J; Boardman K; Su SC; Li X; Chan IS; Parrino J; Annunziato P; Oxman MN;
Clin Infect Dis; 2015 Mar; 60(6):900-9. PubMed ID: 25416754
[TBL] [Abstract][Full Text] [Related]
36. Recombinant Zoster Vaccine (Shingrix
Syed YY
Drugs Aging; 2018 Dec; 35(12):1031-1040. PubMed ID: 30370455
[TBL] [Abstract][Full Text] [Related]
37. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
[TBL] [Abstract][Full Text] [Related]
38. Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
Bastidas A; de la Serna J; El Idrissi M; Oostvogels L; Quittet P; López-Jiménez J; Vural F; Pohlreich D; Zuckerman T; Issa NC; Gaidano G; Lee JJ; Abhyankar S; Solano C; Perez de Oteyza J; Satlin MJ; Schwartz S; Campins M; Rocci A; Vallejo Llamas C; Lee DG; Tan SM; Johnston AM; Grigg A; Boeckh MJ; Campora L; Lopez-Fauqued M; Heineman TC; Stadtmauer EA; Sullivan KM;
JAMA; 2019 Jul; 322(2):123-133. PubMed ID: 31287523
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of an AS01-adjuvanted varicella zoster virus subunit candidate vaccine (HZ/su): a phase-I, open-label study in Japanese adults.
Lal H; Zahaf T; Heineman TC
Hum Vaccin Immunother; 2013 Jul; 9(7):1425-9. PubMed ID: 23584252
[TBL] [Abstract][Full Text] [Related]
40. Natural History of Herpes Zoster in the Placebo Groups of Three Randomized Phase III Clinical Trials.
Curran D; Matthews S; Boutry C; Lecrenier N; Cunningham AL; Schmader K
Infect Dis Ther; 2022 Dec; 11(6):2265-2277. PubMed ID: 36322332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
